




RealRate

PHARMACEUTICAL 2023

Eton Pharmaceuticals Inc
Rank 258 of 471

eTon PHARMACEUTICALS



The relative strengths and weaknesses of Eton Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eton Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Eton Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 10% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	20,004	Assets	25,030
Cost of Goods Sold	6,933	Liabilities	11,952
Intangible Assets	4,754	Expenses	29,511
Liabilities, Current	6,461	Revenues	21,251
Liabilities, Non-Current	107	Stockholders Equity	13,078
Other Assets	200	Net Income	-9,021
Other Compr. Net Income	0	Comprehensive Net Income	-9,021
Other Expenses	0	BaseVar	44,252
Other Liabilities	5,384	ECR before LimitedLiability	105%
Other Net Income	-761	Economic Capital Ratio	234%
Other Revenues	21,251		
Property and Equipment	72		
Research and Development	3,996		
Selling, General and Administrative Expense	18,582		